The in vitro antibacterial activity of gatifloxacin, a new quinolone antimicrobial agent

The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of Chemotherapy Vol. 47; no. Supplement2; pp. 3 - 11
Main Authors Yamamoto, Takao, Tomizawa, Hiroshi, Fukuda, Hideyuki, Hori, Shizuko, Hosaka, Masaki, Yasue, Tokutaro, Oomori, Yasuo
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1999
公益社団法人 日本化学療法学会
Subjects
Online AccessGet full text
ISSN1340-7007
1884-5886
DOI10.11250/chemotherapy1995.47.Supplement2_3

Cover

Abstract The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp. The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum. The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition.
AbstractList The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones.GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp.The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum.The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition. 新キノロン系抗菌薬gatifloxacin (GFLX) のin vitro抗菌力について他の新キノロン系抗菌薬との比較を行った。GFLXはグラム陽性菌, グラム陰性菌, 嫌気性菌およびMycobacterium spp. に対して幅広く強い抗菌力を示した。Staphylococcus aureus subsp. aureusおよびStreptococcus pneumoniaeを含む臨床分離のグラム陽性菌に対するGFLXの抗菌力はnorfloxacin (NFLX), ciprofloxacin (CPFX) およびlevofloxacin (LVFX) より優れ, tosufloxacin (TFLX) およびsparfloxacin (SPFX) と同等であった。腸内細菌科およびブドウ糖非 発酵桿菌を含む臨床分離のグラム陰性菌に対するGFLXの抗菌力はNFLX, SPFXおよびLVFXと同等で, CPFXおよびTFLXよりやや劣っていた。Haemophilus inflenzaeの臨床分離株に対するGFLXの抗菌力はNFLX, CPFX, SPFXおよびTFLXより優れ, LVFXと同等であった。臨床分離のMycoplasma pneumoniaeおよびUreaplasma urealyticum に対するGFLXの抗菌力は, CPFXより優れ, SPFXと同等であった。GFLXの抗菌力は, 培地の種類, 接種菌量, 培地のpH, ヒト血清および尿による影響を受けなかった。一方, Mg++の添加により抗菌力の低下が認められたが, これはCPFXと同程度であった。
The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp. The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum. The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition.
Author Yasue, Tokutaro
Oomori, Yasuo
Yamamoto, Takao
Hosaka, Masaki
Fukuda, Hideyuki
Tomizawa, Hiroshi
Hori, Shizuko
Author_FL 安江 徳太郎
山本 隆雄
大森 康男
保坂 雅喜
福田 秀行
堀 閑子
富澤 寛
Author_FL_xml – sequence: 1
  fullname: 福田 秀行
– sequence: 2
  fullname: 大森 康男
– sequence: 3
  fullname: 山本 隆雄
– sequence: 4
  fullname: 安江 徳太郎
– sequence: 5
  fullname: 富澤 寛
– sequence: 6
  fullname: 堀 閑子
– sequence: 7
  fullname: 保坂 雅喜
Author_xml – sequence: 1
  fullname: Yamamoto, Takao
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Tomizawa, Hiroshi
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Fukuda, Hideyuki
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Hori, Shizuko
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Hosaka, Masaki
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Yasue, Tokutaro
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
– sequence: 1
  fullname: Oomori, Yasuo
  organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd
BackLink https://cir.nii.ac.jp/crid/1390282681266376832$$DView record in CiNii
BookMark eNpdUE1LAzEUDFLBWvsfcvAkbs13skcpfkHBgxU8GZI026bsZtdtqvbfG1oPpZf3Zh4zj2EuwSC20QNwg9EEY8LRnVv5pk0r35tuh8uST5icvG27rvaNj4loegaGWClWcKXEIGPKUCERkhdgvNkEixDGSFBcDsHHfOVhiPA7pL6FJqZgjUu-D6aGGYR838G2gkuTQlW3v8aFeAsNjP4Hfm1DbOucbe9rgutbu_ctc4orcF6ZeuPH_3sE3h8f5tPnYvb69DK9nxVrwnAqSs95hQWzwiPnkLBYWFlJ43mmBGGHnBTeEm6cQgvqpCq5Qo4tLHMUM0FH4PrwN4agc7g8MS0RUUQoTISgUihKsuzzIFtvUs6nuz40pt9p06fgaq9PK9VM6uNKTyg9Mppe-0j_AGCdgXY
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1995.47.Supplement2_3
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate 新キノロン系抗菌薬gatifloxacinのin vitro抗菌力
DocumentTitle_FL 新キノロン系抗菌薬gatifloxacinのin vitro抗菌力
EISSN 1884-5886
EndPage 11
ExternalDocumentID 10008028874
article_chemotherapy1995_47_Supplement2_47_Supplement2_3_article_char_en
GroupedDBID 5GY
ALMA_UNASSIGNED_HOLDINGS
DIK
JSF
KQ8
P2P
RJT
RYH
ID FETCH-LOGICAL-j241t-9e55f164b6e0cc06b16b7f7ae50cc201c0c76eb25ac80d3c789580c4db4c31463
ISSN 1340-7007
IngestDate Fri Jun 27 00:41:44 EDT 2025
Wed Sep 03 06:28:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement2
Language Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j241t-9e55f164b6e0cc06b16b7f7ae50cc201c0c76eb25ac80d3c789580c4db4c31463
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1995/47/Supplement2/47_Supplement2_3/_article/-char/en
PageCount 9
ParticipantIDs nii_cinii_1390282681266376832
jstage_primary_article_chemotherapy1995_47_Supplement2_47_Supplement2_3_article_char_en
PublicationCentury 1900
PublicationDate 1999
PublicationDateYYYYMMDD 1999-01-01
PublicationDate_xml – year: 1999
  text: 1999
PublicationDecade 1990
PublicationTitle Japanese Journal of Chemotherapy
PublicationTitleAlternate Jpn. J. Chemother.
PublicationTitle_FL Jpn. J. Chemother
日化療会誌
日本化学療法学会雑誌
PublicationYear 1999
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 5) Hosaka M, Kinoshita S, Toyama A, et al: Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 36: 293-301, 1995
7) 日本化学療法学会嫌気性菌MIC測定法検討委員会: 嫌気性菌の最小発育阻止濃度 (MIC) 測定法. Chemotherapy 27: 559-560, 1979
1) Hosaka M, Yasue T, Fukuda H, et al: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36: 2108-2117, 1992
9) Taylor-Robinson D, Martin-Bourgon C, Watanabe T, et al: Isolation of Tmycoplasmas from dogs and squirrel monkeys: Biological and serological comparison with those isolated from man and cattle. J Gen Microb 68: 97-107, 1971
10) 日本化学療法学会抗菌薬感受性測定法検討委員会: 微量液体希釈法によるMIC測定法 (微量液体希釈法)-日本化学療法学会標準法-. Chemotherapy 38: 103-105, 1990
11) Timmers K, Sternhlonz R: Ionization and divalent cation dissociation constants of nalidixic acid and oxolinic acid. Bioorganic Chem 9: 145-155, 1978
8) Osada Y, Ogawa H: Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother 23: 509-511, 1983
4) Ishida K, Kaku M, Irifune K, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae: J Antimicrob Chemother 34: 875-883, 1994
2) Tomioka H, Saito H, Sato K: Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 37: 1259-1263, 1993
6) 日本化学療法学会: 最小発育阻止濃度 (MIC) 測定法再改訂について. Chemotherapy 29: 76-79, 1981
3) Wakabayashi E, Mitsuhashi S: In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 38: 594-601, 1994
References_xml – reference: 4) Ishida K, Kaku M, Irifune K, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae: J Antimicrob Chemother 34: 875-883, 1994
– reference: 5) Hosaka M, Kinoshita S, Toyama A, et al: Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 36: 293-301, 1995
– reference: 9) Taylor-Robinson D, Martin-Bourgon C, Watanabe T, et al: Isolation of Tmycoplasmas from dogs and squirrel monkeys: Biological and serological comparison with those isolated from man and cattle. J Gen Microb 68: 97-107, 1971
– reference: 3) Wakabayashi E, Mitsuhashi S: In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 38: 594-601, 1994
– reference: 6) 日本化学療法学会: 最小発育阻止濃度 (MIC) 測定法再改訂について. Chemotherapy 29: 76-79, 1981
– reference: 11) Timmers K, Sternhlonz R: Ionization and divalent cation dissociation constants of nalidixic acid and oxolinic acid. Bioorganic Chem 9: 145-155, 1978
– reference: 7) 日本化学療法学会嫌気性菌MIC測定法検討委員会: 嫌気性菌の最小発育阻止濃度 (MIC) 測定法. Chemotherapy 27: 559-560, 1979
– reference: 10) 日本化学療法学会抗菌薬感受性測定法検討委員会: 微量液体希釈法によるMIC測定法 (微量液体希釈法)-日本化学療法学会標準法-. Chemotherapy 38: 103-105, 1990
– reference: 1) Hosaka M, Yasue T, Fukuda H, et al: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36: 2108-2117, 1992
– reference: 8) Osada Y, Ogawa H: Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother 23: 509-511, 1983
– reference: 2) Tomioka H, Saito H, Sato K: Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 37: 1259-1263, 1993
SSID ssib001106319
ssib050995465
ssib000940262
ssib001168255
ssib038076210
ssib002822060
ssib002670600
ssib058493824
ssj0003212010
Score 1.4489055
Snippet The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones....
The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new...
SourceID nii
jstage
SourceType Publisher
StartPage 3
SubjectTerms gatifloxacin
in vitro抗菌力
新キノロン系抗菌薬
Title The in vitro antibacterial activity of gatifloxacin, a new quinolone antimicrobial agent
URI https://www.jstage.jst.go.jp/article/chemotherapy1995/47/Supplement2/47_Supplement2_3/_article/-char/en
https://cir.nii.ac.jp/crid/1390282681266376832
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Japanese Journal of Chemotherapy, 1999/09/27, Vol.47(Supplement2), pp.3-11
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW6ISFeEAgQA4b8wBMhxY2dr0cETAUET50oT5HjOigtTaAkCPg5_FKO4yT1xqQB1RQ1rpwlvifX5175HhPyiMlCKM2YHyiTrUqD2M8LvFeFZAgGtMa7boqT376L5qfi9TJcTia_nFVLbZNP1c8L60r-x6pog11Nlew_WHa8KBrwHfbFERbG8a9tXFbet7LZ1R6GqMyt9rKp_1f9thAgg0ZEo_hUf5fKCgZIs4-496UtTU690l3PbdkpMpmeH4e1MANnxXxq9qn0HPJqdAb62q0xJ3_SbtqV9OblSv9oN-WYvq239a70PsivbT36GLmV6F97C7mRTisw4C3qTdvIXb3PRxgNg_0sMdzNsN70oruxXpabZYzMbnc71bYtSYQfJr0udu-arRhnD8Fum9MuZxo4Hpc7U7d1239OCqB5MKVy7sUUpk9FjAlqvGbG91PiuFBxZouR4YnFAbkSxPHMLBt98eqNQ1ERgTuSi6BTEXcl8mYRgnCHkkZGr8ihXGBobB-iGv3_KNhTMvC51OxXP54nIuVJX9Fj2AYH92BWdGMY1avk8fDYTy99aDCvNeIQIzBxUJWlQ64WN8j1Hlj0mYX4TTJZy1tkCXjTsqIdvOkZeNMB3rQuqAvvJ1RSgJuO4KZnwE07cN8mpycvF8_nfr8RiL8GwWz8VIdhgbg-jzRTikX5LMrjIpY6xCmeXjEVRzoPQqkStuIqTtIwYUqscqE4qAC_Qw4r_Mu7hIoC4WSoUy3w4ZJL_OGioVAzofM4PyLv7XBkn63aS9a_3dn5kcxEnDmQPH_KnY5yB291RI4xvhmGAkfEXcbyRvwPlB8hPw_uXfL7fXLNSoaY9N8DctjsWn0MQtzkDztE_gbt_bRS
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+in+vitro+antibacterial+activity+of+gatifloxacin%2C+a+new+quinolone+antimicrobial+agent&rft.jtitle=Japanese+Journal+of+Chemotherapy&rft.au=Fukuda+Hideyuki&rft.au=Oomori+Yasuo&rft.au=Yamamoto+Takao&rft.au=Yasue+Tokutaro&rft.date=1999&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=1340-7007&rft.eissn=1884-5886&rft.volume=47&rft.issue=Supplement2&rft.spage=3&rft.epage=11&rft_id=info:doi/10.11250%2Fchemotherapy1995.47.supplement2_3&rft.externalDocID=10008028874
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-7007&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-7007&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-7007&client=summon